Cisplatin-based chemotherapy in recurrent or high risk ovarian granulosa- cell tumor patients

S. Chiara, L. Merlini, E. Campora, M. Bruzzone, S. Giudici, R. Rosso, N. Ragni

Research output: Contribution to journalArticlepeer-review


Nine chemotherapy-naive women with recurrent (2 patients) or high risk factors (bilateral or extraovarian spread, poorly-differentiated tumor, age ≥ 40 years at diagnosis, residual disease after surgery) granulosa-cell tumors were treated with cisplatin, cyclophosphamide with or without doxorubicin (PAC, PC) or cisplatin, etoposide and bleamycin (PVP-16B). Toxicity was acceptable and the most frequently encountered adverse reactions were WHO grade 3 gastrointestinal toxicity in 77% of patients, and grade 3 myelosuppression in 22% of cases. Clinical complete response was achieved in the 2 patients with recurrent disease. Five patients underwent second look surgery which documented: complete response in 3 patients, partial response in 1 patient and progressive disease in 1 case. Median survival was 85 months (range 14-103). Cisplatin-based cytotoxic regimens may be of benefit in the treatment of recurrent or high risk granulosa-cell tumors.

Original languageEnglish
Pages (from-to)314-317
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Issue number4
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Cisplatin-based chemotherapy in recurrent or high risk ovarian granulosa- cell tumor patients'. Together they form a unique fingerprint.

Cite this